Journal of Clinical & Experimental Pathology
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer (EOC) has a significantly
better prognosis than stage III/IV EOC, with about 80% of patients surviving at 5 years (compared with about 20% of those with
stage III/IV EOC). However, 20% of patients with stage I EOC relapse within 5 years. It is therefore crucial that the biological
properties of stage I EOCs are further elucidated. MicroRNAs (miRNAs) have shown diagnostic and prognostic potential in
stage III and IV EOCs, but the small number of patients diagnosed with stage I EOC has so far prevented an investigation of
its molecular features. We profiled miRNA expression in stage I EOC tumours to assess whether there is a miRNA signature
associated with overall and progression-free survival (PFS) in stage I EOC.
We analysed tumour samples from 144 patients (29 of whom relapsed) with stage I EOC gathered from two independent
tumour tissue collections (A and B), both with a median follow-up of 9 years. 89 samples from tumour tissue collection A were
stratified into a training set (51 samples, 15 of which were from patients who relapsed) for miRNA signature generation, and into
a validation set (38 samples, seven of which were from patients who relapsed) for signature validation. Tumour tissue collection B
(55 samples, seven of which were from patients who relapsed) was used as an independent test set. The Cox proportional hazards
model and the log-rank test were used to assess the correlation of quantitative reverse transcription PCR (qRT-PCR)-validated
miRNAs with overall survival and PFS.
A signature of 34 miRNAs associated with survival was generated by microarray analysis in the training set. In
both the training set and validation set, qRT-PCR analysis confirmed that 11 miRNAs (miR-214, miR-199a-3p, miR-199a-5p,
miR-145, miR-200b, miR-30a, miR-30a*, miR-30d, miR-200c, miR-20a, and miR-143) were expressed differently in relapsers
compared with non-relapsers. Three of these miRNAs (miR-200c, miR-199a-3p, miR-199a-5p) were associated with PFS, overall
survival, or both in multivariate analysis. qRT-PCR analysis in the test set confirmed the downregulation of miR-200c in relapsers
compared with non-relapsers, but not the upregulation of miR-199a-3p and miR-199a-5p. Multivariate analysis confirmed that
downregulation of miR-200c in the test set was associated with overall survival (HR 0?094, 95% CI 0?012?0?766, p=0?0272) and
PFS (0.035, 0.004?0.311; p=0.0026), independent of clinical covariates.
miR-200c has potential as a predictor of survival, and is a biomarker of relapse, in stage I EOC.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals